By Sean Farrell
Date: Tuesday 19 Oct 2021
LONDON (ShareCast) - (Sharecast News) - Johnson & Johnson upgraded its full-year guidance after reporting a 3% increase in third-quarter earnings driven by pharmaceutical sales.
Diliuted earnings per share rose to $1.37 in the three months to the end of September from $1.33 a year earlier as sales rose 10.7% to $23.34bn.
Pharmaceutical sales, excluding acquisition and divestitures, rose 13.8% to $12.99bn and consumer health sales increased 5.7% to £3.7bn. J&J reiterated its outlook for $2.5bn of sales from its Covid-19 vaccine after quality problems forced millions of doses to be wasted earlier in 2021.
The US healthcare company upped its annual adjusted earnings forecast to between $9.77 per share and $9.82 per share, from an earlier estimate of $9.60 to $9.70 per share.
Alex Gorsky, J&J's chief executive, said: "Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in pharmaceuticals."
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 152.67 |
Change Today | $ 1.29 |
% Change | 0.85 % |
52 Week High | $174.48 |
52 Week Low | $144.45 |
Volume | 5,547,955 |
Shares Issued | 2,407.08m |
Market Cap | $367,489m |
RiskGrade | 87 |
Strong Buy | 5 |
Buy | 6 |
Neutral | 11 |
Sell | 0 |
Strong Sell | 0 |
Total | 22 |
Time | Volume / Share Price |
15:59 | 100 @ $152.70 |
15:59 | 100 @ $152.70 |
15:59 | 100 @ $152.68 |
15:59 | 100 @ $152.68 |
15:59 | 100 @ $152.68 |
You are here: research